Patent ID: 9164098
Filing Date: 2015-10-20
Classification: G01N

Abstract:
1. A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject to determine an appropriate breast cancer treatment, comprising: providing a breast cancer sample from the subject; measuring amounts of two proteins by mass spectrometry, wherein the two proteins have a molecular weight of 8404 atomic mass units and 8419 atomic mass units, respectively, the molecular weights being assigned to the human cysteine-rich intestinal protein 1 (CRIP1) and a structurally modified variant human cysteine-rich intestinal protein 1, respectively; comparing the amounts of the proteins to control amounts; determining the expression of the human epidermal growth factor receptor 2 to be up-regulated if the amounts of the two proteins compared to the control amounts are increased; and predicting a beneficial effect to Trastuzumab when there is an up-regulated expression of the human epidermal growth factor receptor 2.